Masimo is a leading provider of advanced noninvasive monitoring solutions, focusing on technologies that improve patient care and operational efficiency in healthcare settings. The company leverages ...

Danaher, the NYSE-listed biotechnology and diagnostics company, is to acquire Masimo Corporation, the California-based firm best known for its development of optical pulse oximetry devices widely used ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics portfolio. The acquisition values the device maker at $180 per share and ...

The long Masimo drama has a Hollywood Ending, at least for shareholders. The sale announced on Tuesday 17 February is a rich one–$180 per share, cash. (Masimo was trading in the ~$130/share range last ...

WASHINGTON – Danaher Corporation, a global science and technology company, has entered into a definitive agreement to acquire Masimo Corporation, a specialty diagnostics provider of pulse oximetry and ...

Danaher will acquire pulse oximeter maker Masimo in a $9.9 billion deal, as the life science firm looks to bulk up its diagnostics portfolio. The companies said on Tuesday that Danaher will pay $180 ...

A U.S. jury ruled on November 15, 2025, that Apple must pay Masimo $634 million in a patent infringement case over smartwatch technology, awarding Masimo a major victory after years of litigation.

Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) ...

Garmin is intensifying its research into metabolic health with a newly published patent for non-invasive HbA1c estimation. The USPTO filing—granted in early February—describes a system that uses the ...